

Circadian Rhythm Disruption in Cancer Biology

Christos Savvidis¹ and Michael Koutsilieris²

¹Department of Endocrinology and Metabolism, "Hippocraton" General Hospital, Athens, Greece; and ²Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Circadian rhythms show universally a 24-h oscillation pattern in metabolic, physiological and behavioral functions of almost all species. This pattern is due to a fundamental adaptation to the rotation of Earth around its own axis. Molecular mechanisms of generation of circadian rhythms organize a biochemical network in suprachiasmatic nucleus and peripheral tissues, building cell autonomous clock pacemakers. Rhythmicity is observed in transcriptional expression of a wide range of clock-controlled genes that regulate a variety of normal cell functions, such as cell division and proliferation. Desynchrony of this rhythmicity seems to be implicated in several pathologic conditions, including tumorigenesis and progression of cancer. In 2007, the International Agency for Research on Cancer (IARC) categorized "shiftwork that involves circadian disruption (as) *probably carcinogenic to humans*" (Group 2A in the IARC classification system of carcinogenic potency of an agent) (*Painting, Firefighting, and Shiftwork*; IARC; 2007). This review discusses the potential relation between disruptions of normal circadian rhythms with genetic driving machinery of cancer. Elucidation of the role of clockwork disruption, such as exposure to light at night and sleep disruption, in cancer biology could be important in developing new targeted anticancer therapies, optimizing individualized chronotherapy and modifying lighting environment in workplaces or homes.

Online address: <http://www.molmed.org>

doi: 10.2119/molmed.2012.00077

INTRODUCTION

The term "circadian" is derived from the Latin phrase *circa diem*, which means "about a day." The suprachiasmatic nucleus (SCN) in the anterior hypothalamus serves as a circadian master clock, or an endogenous biological oscillator, that controls biochemical, physiological and behavioral rhythms, entrained by light and other external signals (1). The first reference of periodicity in medicine was made by Hippocrates when describing the fever's course: "The quotidian, tertian, and quartan fevers. . . ." (2). SCN also has the unique ability to provide critical stimulus for resetting its clock phase in direct response to a light signal, which is relayed from the retina via the retinohypothalamic tract (3).

Circadian rhythms are generated by a set of clock genes and proteins (4) regulating many functions, including the ability to fall asleep or to snap out of sleep into wakefulness (5), body temperature (6), blood pressure (7), hormone biosynthesis (8), digestive secretion (9) and immune responses (10). Further to the central nervous system, circadian rhythmicity is present in peripheral tissues, too. Individual normal cells and even cancer cells keep circadian time by expressing similar clock genes (11). Circadian clocks in peripheral tissues regulate the expression of specific genes and synthesis of products, such as thymidylate synthase, p21 and Wee-1, which control DNA synthesis, cell division cycle and cell proliferation, coordinating physiological processes in a circadian manner (12–14). It is noteworthy

that, in the industrialized world, there is a change in the lighted environment from a sun-based system to an electricity-based system. Modern lifestyle forces more people to work late shifts, to change shifts regularly or to spend more time doing other activities, prolonging the exposure to light. Epidemiological studies correlate disruption of circadian rhythms with incidence of breast cancer and poorer prognosis of the disease (15,16). In mouse models, data show that disturbed circadian clock gene expression and disruption of circadian rhythms correlate with tumor development and tumor progression (17).

REGULATION OF CIRCADIAN CLOCK GENES

Timing of circadian clocks is established in a cell-autonomous manner by a self-sustaining molecular oscillator that consists of intertwined negative and positive transcription/translation-based feedback loops in SCN (18) and peripheral tissues (19,20). Human period (*hPer1*, -2 and -3) and cryptochrome (*Cry1* and -2) clock genes are components of the SCN circadian clockwork (21–23). Protein products of these genes (PER and CRY) inhibit their own transcriptional activators: circadian

Address correspondence to Christos Savvidis, 9 Polyfimou, Zografos, Athens 15771, Greece. Phone: +30-6972878089 or +30-2107750273, Fax: +30-2107750273; E-mail: csavvidis@med.uoa.gr.

Submitted February 21, 2012; Accepted for publication July 17, 2012; Epub (www.molmed.org) ahead of print July 17, 2012.

[*JARID1A*]) and protein translation (B-cell translocation gene 2 [BTG2], poly(A) binding protein interacting protein 2 [PAIP2A]) (45). However, there are other molecules that interact with clock genes and have important effects on circadian oscillation processes. For example, the receptor for activated protein kinase C-1 (RACK1) is a protein that mediates or regulates functions of PER1 (46). Activation of the MAPK cascade is able to trigger the induction and resetting of the circadian oscillation of gene expression (47). Fluctuating levels of circulating ovarian steroid hormones during the estrous cycle regulate the rhythm of clock gene expression in reproductive tissues (48).

ROLE OF CIRCADIAN CLOCK GENES IN CANCER

Core circadian genes seem to be important in tissue homeostasis and tumorigenesis. Disruption of circadian rhythms is associated with various forms of cancer in humans. There is increasing evidence that links dysfunction of the clockwork with the pathogenesis of cancer. The master circadian clock in SCN is an endogenous timekeeping system and controls multiple peripheral clocks in other peripheral tissues of the body. Many studies have shown that circadian clock gene deregulation is implicated in the development of cancer and other diseases. Disruption of circadian rhythms accelerates tumor progression, and potentially restoring circadian rhythms should improve prognosis. Decreased expression levels of *Per1* and *Per2* genes are observed in sporadic and familial breast tumors when compared with normal breast tissues. The *Per1* gene shows lower expression levels in familial forms of breast cancer when compared with sporadic forms, suggesting that a potential deregulation of the circadian clock may contribute to the inherited form of the disease (49). Methylation of promoters of the *Per1* and *Cry1* genes may lead to survival of breast cancer cells through inactivation of expression of these genes and disruption of the circadian cell rhythm (50). Moreover, a significantly higher risk of breast cancer associated

with clock genetic polymorphisms is observed in Chinese populations (51). *Bmal1* epigenetic inactivation, via cytosine-guanine (CpG) island promoter hypermethylation, contributes to the development of hematologic malignancies, non-Hodgkin lymphoma and acute lymphocytic leukemia, by disrupting cellular circadian clock, leading to loss of circadian rhythmicity of target genes such as *c-myc*, catalase and p300 (52). Genetic variations in *Cry2* and Ala394Thr functional polymorphism in the circadian gene neuronal PAS domain protein 2 (NPAS2) increase the inherited susceptibility to non-Hodgkin lymphoma (53,54). Methylation of CpG sites of the *hPer3* gene is observed in patients with chronic myeloid leukemia (55). Prostate cancer is the most common cancer, excluding skin cancer, and the second leading cause of cancer-related death in men in the United States (56). The only well-established risk factors for prostate cancer are older age, family history of the disease and race. Circadian disruption may be a novel risk factor in prostate tumorigenesis. Results from a population-based case-control study provide evidence for an association of genetic variations in circadian genes with prostate tumorigenesis (53). Clock genes and the androgen receptor are expressed with circadian oscillations in the normal prostate. *Per1* inhibits transcriptional activity of the androgen receptor, and downregulation of this clock gene seems to contribute to prostate tumorigenesis (57). Significant dysregulation of clock genes is one of the basic mechanisms driving the mesothelioma process (58). The expression of protooncogene *c-myc* is under circadian regulation, in the same phase with *Per1*, in the neuroblastoma cell line (59). Expression rates of *Per1* and *Per2* are lower in glioma cells when compared with non-malignant cells (60,61). *Per1* and *Per2* seem to be involved in suppressing the proliferation of pancreatic cancer cells (62,63).

Circadian disruption promotes liver carcinogenesis and possibly participates in its initiation, as observed in mice exposed to the hepatic carcinogen diethylnitrosamine (64). Hepatoma has the same

circadian oscillation pattern with normal cells but is less sensitive to circadian timing signals, such as mealtimes, leading to dissociation of circadian rhythms in cancer and healthy cells (65).

The expression levels of *Cry1* and *Bmal1* core clock genes are correlated with clinicopathological parameters in epithelial ovarian cancer, and combination of low expression levels of both genes is an independent prognostic factor, as are stage and histological subtype (66). Disruption of the circadian clock, after methylation of the promoter CpG in *Per1*, *Per2* or *Cry1* circadian genes, is possibly involved in the development of endometrial cancers (67). The expression level of *TIM* was higher in the tumor tissue of colorectal cancer patients (68). The possible link of peripheral clock regulation in peripheral tissues with particular cancers is further supported by the following data. Several nuclear receptors are implicated in expression of peripheral clocks and constitute molecular links between clock genes and metabolic functions (reviewed in [69]). Expression levels of *PER1-3*, *CRY1-2*, *CK1e* and *TIM* are downregulated in patients with chronic myeloid leukemia (70). Tumor suppression through the ATM-p53 signaling is a clock-controlled physiological function, and disruption of this function leads to myc oncogenic activation in mice (71). β -Catenin increases β -TrCP (β -transducin repeat-containing protein) levels and shortens PER2 protein half-life, suggesting a possible mechanism for intestinal epithelial neoplastic transformation (72). Implication of circadian genes in various forms of cancer is supported by these data, and ongoing research will provide evidence to elucidate their biological role.

CIRCADIAN RHYTHMICITY IN CANCER GENETICS

DNA Repair and Circadian Rhythmicity

The circadian clock determines the strength of cellular responses to DNA damage, including DNA repair. DNA repair pathways maintain genetic stability,

protecting DNA integrity from exogenous and/or endogenous stimuli (73,74). Several components of these pathways seem to be entrained by circadian oscillations. Nucleotide excision repair is a DNA repair mechanism that prevents genomes from damage caused by several sources, such as ultraviolet light irradiation and chemical mutagens (75). Nucleotide excision repair in the mouse brain seems to exhibit circadian periodicity, mainly mediated by xeroderma pigmentosum A, a DNA damage recognition protein (76,77). Tip60, a histone acetylase of chromatin, with DNA damage response and repair competency (78), is overexpressed in cisplatin-resistant cells and its silencing sensitizes cells to this cancer chemotherapeutic agent (79). In the same study, the expression of Tip60 is regulated by the circadian transcription factor *Clock*, providing evidence that DNA repair through histone acetylation is under circadian regulation. The high mobility group box 1 (Hmgb1) protein is involved in DNA mismatch repair (80) and shows a circadian rhythmic expression in rat retina (81). Apurinic/aprimidinic endonuclease (APE) is an enzyme component of DNA base excision repair (82). The APE/Ref-1 gene is highly expressed in SCN, the main circadian pacemaker in mammals (83). However APE/Ref-1 mRNA levels do not show circadian patterns of expression (83).

Cell Proliferation and Cancer Cell Growth Are Under Clock Regulation

Proliferation rhythm of tumor cells follows a cyclical pattern different from that in normal tissues (84–87). Disruption of cellular circadian rhythm is associated with alterations in cancer cell proliferation. Downregulation of *Per1* or *Per2* increases cancer cell growth *in vitro* only at certain specific times of the day and enhances time-dependent tumor growth *in vivo* (88). *Per1* has tumor suppressor function (89) and inhibits breast cancer cell proliferation and tumor growth in a circadian expression pattern (90). Downregulation of *Per2* accelerates breast cancer cell proliferation and tumor growth in a circadian time-dependent manner *in*

vivo (91). Mammalian *Per2* (*mPer2*)-deficient mice have tumor occurrences indicating tumor suppression function of *mPer2* (92). Clock mutation significantly inhibits cell growth and proliferation through upregulation of cell cycle inhibitory genes and reduced ability of mutant cells to respond to mitogenic signals (93). In contrast, disruption of the circadian clock, because of deficiency of the functional CLOCK protein, does not affect the rate of carcinogenesis in mice after exposure to ionizing radiation (94). These data suggest the existence of composite relations between genotoxic stress-induced carcinogenesis and the circadian clock. DNA synthesis in tumor cells seems to be modulated by several factors such as platelet-derived growth factor (PDGF) (95). PDGF signaling is activated during tumor development (96–98) and is related to tumor vascularization (99), adhesion, invasion (100) and aggressiveness (101) of cancer cells. Inhibition of this pathway synchronizes DNA synthesis in tumor cells with the rhythm of DNA synthesis in normal bone marrow cells (95). DNA synthesis and telomerase activity, which prevents cells from apoptosis (102), are expressed with a circadian pattern in hepatic cancer cells (103). Interferons (IFNs) are multifunctional cytokines that have antitumor activity, and their receptor shows a diurnal rhythm of expression in implanted-tumor cells (104), showing the importance of dosing time for IFN- β (105).

Mechanisms of Action of Circadian Genes in Cancer

Downregulation of *Per2* increases β -catenin protein levels and its target cyclin D, leading to cell proliferation in colon cancer cell lines and intestinal and colonic polyp formation. This finding suggests that the *Per2* gene product suppresses tumorigenesis in the small intestine and colon by downregulation of β -catenin and β -catenin target gene signaling pathways (106,107). Increased β -catenin affects the circadian clock and enhances PER2 clock protein degradation in colon cancer cells (107). Suppres-

sion of human β -catenin expression inhibits cellular proliferation in intestinal adenomas (108).

Disruption of the peripheral intestinal circadian clock may, in part, contribute to intestinal epithelial neoplastic transformation of human colorectal cancer. The circadian expression of dihydropyrimidine dehydrogenase (DPD), an enzyme that is implicated in the metabolism of the anticancer drug 5-fluorouracil, is possibly regulated by *Per1* in high-grade colon tumors (109). Transferrin receptor 1 (TfR1) is a cell surface receptor required for iron delivery from transferrin to cells (110). Overexpression of TfR1 is associated with an increased rate of cell proliferation and malignant progression to colorectal cancer (111,112). TfR1 shows a 24-h rhythm of expression activated by the clock-controlled gene c-Myc in colon cancer-bearing mice (113). There is also a significant decrease of both estrogen receptor beta (ER- β) and *Per1* in undifferentiated colorectal tumors (114). Casein kinase 1 ϵ (CK1 ϵ) phosphorylates PER2 protein, leading to degradation of PER2 by 26S proteasome (115,116). Thus, inhibition of CK1 ϵ by IC261, a kinase domain inhibitor, exerts a growth-suppressive effect of PER2 (117). Methylation of the *Per* gene promoters causes deregulation in the expression of PER proteins, resulting in proliferation of breast cancer cells (118). *Per1* mediates inhibition of proliferation of a human pancreatic cancer cell line (MIA-PaCa2) by tumor necrosis factor (TNF)- α . The expression of *Per1* is suppressed by TNF- α , and knockdown of *Per1* decreases proliferation of MIA-PaCa2 cells (119). Chronic jetlag increases the risk of various cancers in mice, and circadian gene mutations make mutant mice more prone to cancer (71). Clock and *Per2* protein levels are decreased, whereas Bmal1 protein levels are increased in prostate cancer (PCa) cells when compared with normal human prostate epithelial cells. Melatonin resynchronizes deregulated core clock genes in human PCa cells by upregulation of mRNA levels of Clock and *Per2* and downregulation of Bmal1 mRNA (120),

suggesting the preventive effects of melatonin against loss of rhythmicity, that is, observed during tumor progression (121).

Epigenetic Modifications of Circadian Clock Genes

Epigenetic modifications are heritable changes that take place independently of changes in the DNA sequence and are involved in regulation of gene transcription (122). DNA methylation and histone modifications are the main epigenetic mechanisms. In mammals, DNA methylation occurs primarily through addition of a methyl group to the 5' carbon of cytosine located next to a guanine in CpG dinucleotides (123). Changes in DNA methylation accompany tumor initiation and progression (124,125). Promoter regions of tumor suppressor genes are methylated in cancer, resulting in gene silencing in contrast to normal cells, where most CpG islands are unmethylated (126). In addition, the consequence of hypomethylation leads to genomic instability through an opening of the chromatin and subsequent chromosomal breakage (127). Acetylation is the main, but not the only, posttranslational modification of nucleosomal histones that is involved in cancer initiation and progression (128,129). Histone acetylation is controlled by the opposing action of histone acetyltransferase (HAT) and histone deacetylases (HDAC) enzyme (130). Disruption of HAT or HDAC activity may play a key role in tumor invasion and metastasis (131).

INTERACTIONS BETWEEN ENVIRONMENT AND CLOCK GENES

Activation of aryl hydrocarbon receptor (AhR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibits *Per1* gene expression by blocking CLOCK:BMAL1 heterodimer binding to enhancer boxes (E-boxes) in the *Per1* promoter (132). This is a potential mechanism by which environmental pollutants may contribute to the development of carcinogenesis through disruption of circadian rhythm and repression of clock. Disruption of

clock genes, *Per1* and/or *Per2*, modifies mammary gland (133,134) and liver (134,135) responses to the environmental toxin TCDD by altering the inductive effects of TCDD on expression of cytochrome P450 genes (136). AhR activation by TCDD changes the circadian rhythms of murine hematopoietic stem progenitor cells (137) and mouse ovary (138). *Per1* sensitizes cancer cells to activate their apoptotic machinery after DNA damage from double-strand break-causing agents, such as ionizing irradiation (89).

INTERACTIONS OF THE CLOCK WITH THE STEROID HORMONE RECEPTORS AND IMPACT ON CANCER

Glucocorticoid receptor (GR) is activated by glucocorticoids, a class of steroid hormones (139). Subsequent to, activation of GR involves (a) its nuclear translocation, (b) transactivation or binding to glucocorticoid-responsive element to regulate gene expression (140,141).

Stress has been associated with cancer progression through the glucocorticoid receptor system. GR expression is implicated in various forms of cancer such as prostate cancer and renal cell neoplasms (142,143). In human small cell lung cancer cells, GR expression is lost by DNA methylation, causing their increased survival (144). In contrast, high expression levels of GR are associated with shorter relapse-free survival in estrogen receptor-negative breast cancer (145). GR and core clock proteins (PER2 and CLOCK) are coexpressed in bronchiolar epithelial cells (146), and CLOCK-related genes regulate glucocorticoid action in all tissue through attenuation of the transcriptional activity of GR (147,148). A possible mechanism is the acetylation of several lysine residues of GR and concomitant attenuation of GR binding to glucocorticoid response elements (149). Desynchronization of circadian clock genes is possibly implicated in the role of the stress system in cancer progression through these mechanisms. As mentioned above, expression rhythms of circadian genes (*Per1/2* and *Bmal1*) are modulated by the levels of

ovarian steroid hormones in both reproductive and nonreproductive tissues (48). In addition, progesterone seems to cause acute increases of *Per1*, *Per2* and *Bmal1* expression in human breast cancer MCF-7 cells (48). Single nucleotide polymorphisms (SNPs) of the Clock gene are significantly associated with estrogen receptor/progesterone receptor (ER/PR)-negative cases of breast cancer (150). SNPs of NPAS2 have been linked to the risk of prostate cancer risk and hormone-related breast cancer (53,151). The possible mechanism implicates the aryl hydrocarbon receptor nuclear translocator-like (ARNTL)/NPAS2 heterodimer that suppresses transcription of the oncogene *c-myc* (152). Increased expression of *Per2* in breast cancer cells leads to tumor apoptosis, possibly acting as an estrogen-inducible ER- α corepressor (153). CLOCK has histone acetyltransferase activity and acts as a coactivator of ER α , explaining the association between circadian rhythm disruption and breast cancer (154). Association of clock genes and proteins with various forms of cancers is summarized in Table 1.

CLOCK GENES IN CANCER PROGRESSION, METASTASIS AND ANGIOGENESIS

Circadian disruption promotes tumor growth and angiogenesis, especially growth of both fibroblasts and vascular endothelial cells, induced by overexpression of wingless-type MMTV integration site family, member 10A (*WNT10A*) in tumor stroma cells as a result of increased levels of oxidative stress (155). Elevated expression of the *mPer1* gene found in tumor stroma may affect interactions between cancer and stromal cells and is consequently involved in cancer progression and metastasis (156). The 24-h rhythm of methionine aminopeptidases, which are involved in tumorigenesis (157) and tumor angiogenesis (157,158), is regulated by transcription of clock genes, enhanced by mCLOCK:mBMAL1 heterodimer and inhibited by mPER2 or mCRY1 (159). However, the effects of exogenous melatonin on tumor growth de-

Table 1. Association of clock genes and proteins with various forms of cancers.

Cancer type (and effect)	Trigger	Circadian genes/proteins	Reference
Sporadic and familiar breast tumors	Decreased expression levels	<i>Per1, Per2</i>	49
Familiar breast tumors (than sporadic)	Lower expression levels	<i>Per1</i>	49
Survival of breast cancer cells	Methylation of promoters	<i>Per1, Cry1</i>	50
Proliferation of breast cancer cells	Methylation of promoters	<i>Per</i>	118
Higher risk of breast cancer	Polymorphisms	<i>Clock</i>	51
Inhibits breast cancer cell proliferation and tumor growth	Expression	<i>Per1</i>	89
Breast cancer cell proliferation and tumor growth	Downregulation	<i>Per2</i>	91
ER/PR-negative cases of breast cancer	SNPs	<i>Clock</i>	150
Breast cancer	Histone acetyltransferase activity	CLOCK (protein)	154
Tumor apoptosis in breast cancer	Increased expression	<i>Per2</i>	153
Prostate cancer risk and hormone-related breast cancer	SNPs	<i>NPAS2</i>	53,151
Non-Hodgkin lymphoma and acute lymphocytic leukemia	Epigenetic inactivation (via CpG hypermethylation)	<i>Bmal1</i>	52
Non-Hodgkin lymphoma	Genetic variations, functional polymorphism	<i>Cry2, NPAS2</i>	53,54
Chronic myeloid leukemia	Methylation	<i>Per3</i>	55
Prostate cancer	Downregulation	<i>Per1</i>	57
Prostate cancer	Increased expression level	<i>Per2, Clock</i>	120
Prostate cancer	Decreased expression levels	<i>Bmal1</i>	120
Glioma	Lower expression rates	<i>Per1, Per2</i>	60,61
Suppression of proliferation in pancreatic cancer	Expression	<i>Per1, Per2</i>	62,63
Proliferation of human pancreatic cancer cell line	Knockdown	<i>Per1</i>	119
Epithelial ovarian cancer	Low expression levels	<i>Cry1, Bmal1</i>	66
Endometrial cancer	CpG methylation	<i>Per1, Per2, Cry1</i>	67
Colorectal cancer	Increased expression level	<i>Tim</i>	68
Colon cancer	Downregulation	<i>Per2</i>	106,107
Undifferentiated colorectal tumors	Decreased expression levels	<i>Per1</i>	114
Chronic myeloid leukemia	Downregulation	<i>Per1, Per2, Per3, CRY1-2, TIM</i>	70
Intestinal epithelial neoplastic transformation	PER2 protein degradation	<i>Per2</i>	72

pend on the timing of administration (121). The laminin receptor 1 (Lamr1) is important in several physiological and pathological processes, including cell differentiation and viability, cancer development, invasion, migration and metastasis (160–163). Lamr1 interacts with human circadian clock protein hPer1 but does not have circadian pattern of expression (164). CLOCK:BMAL1 and sirtuin 1 (SIRT1) form a chromatin regulatory complex at promoters of clock-controlled genes (165). Sirtuins (SIRT proteins) are a unique class of type III (NAD)-dependent HDACs, which are important in the regulation of gene expression and especially in gene silencing (166). However, this activity shows oscillations in a circadian manner contributing to circadian control (165). SIRT1 is involved in the development of various cancers such as prostate (167), breast (168)

and colorectal (169) and in chemotherapeutic drug resistance of cancer cells (reviewed in [170]).

MELATONIN AND CANCER

In 2007, the International Agency for Research on Cancer categorized “shift-work that involves circadian disruption [as] probably carcinogenic to humans” (Group 2A in the IARC classification system of carcinogenic potency of an agent) (171). Light during the night can suppress melatonin, disrupting circadian rhythms (172). Melatonin (5-methoxy-N-acetyltryptamine) is a hormone of the circadian system, synthesized in the pineal gland and retina (reviewed in [173,174]). In patients with untreated non-small-cell lung cancer (NSCLC) melatonin/cortisol mean nocturnal level ratio and melatonin nocturnal levels are

decreased (175,176). These results may indicate a neuro-immune-endocrine system dysfunction. Melatonin concentrations progressively decrease after standard chemotherapy in NSCLC patients (176). Melatonin can resynchronize a rhythmic pattern of gene expression, correcting defects in expression patterns of various circadian rhythm genes responsible for cancer development (120). Melatonin inhibits myeloperoxidase catalytic activity (177), which is important in the pathogenesis of cancer (178,179). Melatonin has a protective effect against the DNA-damaging action of hydrogen peroxide, by chemical inactivation of this DNA-damaging agent and stimulation of DNA repair (180). Melatonin inhibits tumor signal transduction and metabolic activity of cancer cells, leading to suppression of growth of human breast

cancer via activation of melatonin receptor MT1 (181). Disruption of nocturnal circadian melatonin signal by light at night upregulates tumor metabolism, stimulating its growth (182). Women with total visual blindness have a lower risk of breast cancer than blind women with light perception (183). The antiproliferative ability of melatonin is associated with its uptake into human androgen-dependent LNCaP and androgen-independent PC-3 prostate cancer cells, mainly mediated by an active transport (184).

Preventing low-wavelength light from reaching the retina, for example, by using optical filter goggles may protect shift workers from bright-light suppression of melatonin (185). If epidemiologic and basic science evidence leads to a “proof of causality” of adverse effects from light at night, then lighting standards and building designs should be developed with consideration of the circadian system both at night and during the day, to minimize or eliminate adverse consequences for human health (186–188).

CIRCADIAN RHYTHMS IN CANCER MANAGEMENT

The most important principle of chronomodulated therapeutics against various forms of cancer is to create a balance between effectiveness and adverse toxic effects of drugs. The circadian clock is responsible for rhythmicity of several physiological processes that in turn influence efficiency and tolerance of pharmacotherapy. Chronomodulated infusion of fluorouracil, leucovorin and oxaliplatin for 4 d achieves similar survival when compared with conventional 2-d delivery of the same drugs and acceptable tolerability, with more incidences of diarrhea with 4-d delivery and neutropenia with 2-d delivery. These results were observed in patients with metastatic colorectal cancer in a multicenter randomized phase III trial (189). However, chronomodulated hepatic arterial infusion multidrug chemotherapy shows antitumor activity and is well tolerated in patients with metastatic colorectal cancer after failure of several cur-

rent standard therapeutic options (190). Combination of cetuximab, a chimeric monoclonal antibody directed against the extracellular domain of epidermal growth factor receptor, with circadian chronomodulated chemotherapy can be used effectively in initially unresectable residual metastatic colorectal cancer (191). In a phase II study, use of chronochemotherapy composed of 5-fluorouracil and leucovorin, and local hyperthermia combined with preoperative radiation therapy for locally advanced low-rectal adenocarcinoma had high antitumor activity rate and low incidence of adverse effects (192). Patients with ovarian cancer demonstrate altered diurnal cortisol rhythms, with significantly higher afternoon and nocturnal cortisol levels and lower cortisol variability when compared with patients with benign disease or healthy women (193). Dysregulation in rhythmic function of the hypothalamic-pituitary-adrenal axis is described in breast cancer survivors (194,195) or individuals with metastatic disease (196), in patients scheduled for lumbar disc surgery (197), in metastatic colorectal cancer patients (198) and in patients with cancer-related depression (193,199). Various anticancer agents are implicated in cancer therapeutics after circadian principles. Dietary methylselenocysteine (3 ppm selenium) given for 30 d significantly enhances circadian expression of circadian and growth-regulatory genes that are disrupted by nitrosomethylurea (200). Nitrosomethylurea-induced mammary carcinogenesis in rats is inhibited by methylselenocysteine, possibly through upregulation of circadian oscillations of *Per2* (201). As it mentioned above downregulation of *Per2* accelerates breast cancer (91). The *Per2* gene intratumoral delivery induces apoptosis and inhibits tumorigenesis in C57BL/6 mice transplanted with Lewis lung carcinoma (202). Antitumor effect and tolerability of Seliciclib, a cyclin-dependent kinase inhibitor in mice bearing Glasgow osteosarcoma, is found to depend on circadian rhythmicity (203). Biological pa-

rameters of a tumor, such as its growth kinetics, can affect the timing of optimal chronomodulated treatment, indicating the importance of tailoring these treatments for individual patients. The length of the cell cycle targeted by treatment and proliferation rate of cancer cells are important parameters to define the most effective time to administer cell cycle-specific drugs (204). The severity of acute gastrointestinal mucositis in patients undergoing radiotherapy is significantly increased when therapy is applied in the morning compared with the evening arm, implying that function of intestinal mucosa of the human intestine is possibly under circadian rhythmicity (205). In a retrospective review of local control, frequency of central nervous system-related cause of death and survival, in patients treated with gamma knife radiosurgery for metastatic NSCLC, had better outcomes in procedures earlier in the day versus later in the day (206). Various studies have indicated that toxicity and anticancer efficacy of anticancer drugs can be significantly modified by circadian stage of administration (reviewed in [203,207,208]). Drugs that target proliferation pathways and mimic or control rhythmicity increase susceptibility of cancer cells and thus improve their therapeutic index when given at specific times of day. Timing of any therapy targeting a cancer cell proliferation-related pathway will work substantially better if it is given at certain times within the day, when cancer cell proliferation is most active (reviewed in [209]). A way to optimize current therapies is the elucidation of links between clock genes and drug pharmacodynamic and pharmacokinetic parameters, resulting in development of new therapeutic strategies (210).

SUMMARY

Circadian genes have clock functions that regulate expression of other genes with circadian rhythmicity, resulting in daily oscillations of proteins. Therefore, disruption of clock damages organization of these gene and protein expres-

sions, leading to deregulated cell proliferation and subsequent tumorigenesis. Circadian genes also have nonclock functions, which are important in regulation of cell cycle progression, DNA damage response and genomic stability. Clock and nonclock functions constitute the association between disruption of circadian rhythmicity and cancer.

A major consequence of modern lifestyle is disruption of circadian rhythms. Circadian disruptions induced by light at night, genetic or epigenetic variations in circadian genes and interactions between genes and environment form a set of data that propose that some cancer cases could be explained by these mechanisms. Elucidation of molecular mechanisms that form a link between disruption of circadian rhythm and cancer and determination of how a disrupted circadian peripheral clock contributes to neoplastic transformation is fundamental to provide essential leads developing future novel circadian clock-based strategies for cancer prevention, control and therapeutic intervention.

DISCLOSURE

The authors declare that they have no competing interests as defined by *Molecular Medicine*, or other interests that might be perceived to influence the results and discussion reported in this paper.

REFERENCES

- Albrecht U. (2006) Orchestration of gene expression and physiology by the circadian clock. *J. Physiol. Paris*. 100:243–51.
- Hippocrates. (1868) *On the Sacred Disease* [Internet]. Adams CD, ed. and trans. Dover: New York. Available from: <http://www.chlt.org/sandbox/dh/Adams/page.354.a.php>
- Amir S, Stewart J. (1999) The effectiveness of light on the circadian clock is linked to its emotional value. *Neuroscience*. 88:339–45.
- Benca R, et al. (2009) Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges. *Brain Res. Rev.* 62:57–70.
- Wulff K, Porcheret K, Cussans E, Foster RG. (2009) Sleep and circadian rhythm disturbances: multiple genes and multiple phenotypes. *Curr. Opin. Genet. Dev.* 19:237–46.
- Cajochen C, et al. (2005) High sensitivity of human melatonin, alertness, thermoregulation, and heart rate to short wavelength light. *J. Clin. Endocrinol. Metab.* 90:1311–6.
- Agarwal R. (2010) Regulation of circadian blood pressure: from mice to astronauts. *Curr. Opin. Nephrol. Hypertens.* 19:51–8.
- Oster H, Damerow S, Hut RA, Eichele G. (2006) Transcriptional profiling in the adrenal gland reveals circadian regulation of hormone biosynthesis genes and nucleosome assembly genes. *J. Biol. Rhythms*. 21:350–61.
- Froy O. (2010) Metabolism and circadian rhythms—implications for obesity. *Endocr. Rev.* 31:1–24.
- Keller M, et al. (2009) A circadian clock in macrophages controls inflammatory immune responses. *Proc. Natl. Acad. Sci. U. S. A.* 106:21407–12.
- Wood PA, Du-Quiton J, You S, Hrushesky WJM. (2006) Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. *Mol. Cancer Ther.* 5:2023–33.
- Lincoln DW, Hrushesky WJM, Wood PA. (2000) Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. *Int. J. Cancer*. 88:479–85.
- Matsuo T, et al. (2003) Control mechanism of the circadian clock for timing of cell division in vivo. *Science*. 302:255–9.
- Gréchez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. (2008) The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. *J. Biol. Chem.* 283:4535–42.
- Stevens RG. (2005) Circadian disruption and breast cancer: from melatonin to clock genes. *Epidemiology*. 16:254–8.
- Schernhammer ES, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. *J. Natl. Cancer Inst.* 93:1563–8.
- Sahar S, Sassone-Corsi P. (2007) Circadian clock and breast cancer: a molecular link. *Cell Cycle*. 6:1329–31.
- Kiyohara YB, et al. (2006) The BMAL1 C terminus regulates the circadian transcription feedback loop. *Proc. Natl. Acad. Sci. U. S. A.* 103:10074–9.
- Balsalobre A, Damiola F, Schibler U. (1998) A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell*. 93:929–37.
- Oishi K, et al. (2003) Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. *J. Biol. Chem.* 278:41519–27.
- Bae K, et al. (2001) Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock. *Neuron*. 30:525–36.
- Kume K, et al. (1999) mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. *Cell*. 98:193–205.
- Shearman LP, et al. (2000) Interacting molecular loops in the mammalian circadian clock. *Science*. 288:1013–9.
- Chen R, et al. (2009) Rhythmic PER abundance defines a critical nodal point for negative feedback within the circadian clock mechanism. *Mol. Cell*. 36:417–30.
- Langmesser S, Tallone T, Bordon A, Rusconi S, Albrecht U. (2008) Interaction of circadian clock proteins PER2 and CRY with BMAL1 and CLOCK. *BMC Mol. Biol.* 9:41.
- Jung H, et al. (2003) Involvement of CLOCK:BMAL1 heterodimer in serum-responsive mPer1 induction. *Neuroreport*. 14:15–9.
- Kamae Y, Tanaka F, Tomioka K. (2010) Molecular cloning and functional analysis of the clock genes, clock and cycle, in the firebrat *Thermobia domestica*. *J. Insect Physiol.* 56:1291–9.
- Kondratov RV, et al. (2003) BMAL1-dependent circadian oscillation of nuclear CLOCK: post-translational events induced by dimerization of transcriptional activators of the mammalian clock system. *Genes Dev.* 17:1921–32.
- King DP, et al. (1997) Positional cloning of the mouse circadian clock gene. *Cell*. 89:641–53.
- Vielhaber EL, Duricka D, Ullman KS, Virshup DM. (2001) Nuclear export of mammalian PERIOD proteins. *J. Biol. Chem.* 276:45921–7.
- Kawamoto T, et al. (2004) A novel autofeedback loop of Dec1 transcription involved in circadian rhythm regulation. *Biochem. Biophys. Res. Commun.* 313:117–24.
- Butler MP, et al. (2004) Dec1 and Dec2 expression is disrupted in the suprachiasmatic nuclei of clock mutant mice. *J. Biol. Rhythms*. 19:126–34.
- Hamaguchi H, et al. (2004) Expression of the gene for Dec2, a basic helix-loop-helix transcription factor, is regulated by a molecular clock system. *Biochem. J.* 382:43–50.
- Nakashima A, et al. (2008) DEC1 modulates the circadian phase of clock gene expression. *Mol. Cell. Biol.* 28:4080–92.
- Porterfield VM, Mintz EM. (2009) Temporal patterns of light-induced immediate-early gene expression in the suprachiasmatic nucleus. *Neurosci. Lett.* 463:70–3.
- Tamai TK, Young LC, Whitmore D. (2007) Light signaling to the zebrafish circadian clock by Cryptochrome 1a. *Proc. Natl. Acad. Sci. U. S. A.* 104:14712–7.
- Cuesta M, Mendoza J, Clesse D, Pévet P, Challet E. (2008) Serotonergic activation potentiates light resetting of the main circadian clock and alters clock gene expression in a diurnal rodent. *Exp. Neurol.* 210:501–13.
- Cailotto C, et al. (2009) Effects of nocturnal light on (clock) gene expression in peripheral organs: a role for the autonomic innervation of the liver. *PLoS One*. 4:e5650.
- Hamada T, Honma S, Honma K-I. (2011) Light responsiveness of clock genes, Per1 and Per2, in the olfactory bulb of mice. *Biochem. Biophys. Res. Commun.* 409:727–31.
- Honma S, et al. (2002) Dec1 and Dec2 are regulators of the mammalian molecular clock. *Nature*. 419:841–4.
- Sangoram AM, et al. (1998) Mammalian circadian

- autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. *Neuron*. 21:1101–13.
42. Nielsen AF, Gloggnitzer J, Martinez J. (2009) MicroRNAs cross the line: the battle for mRNA stability enters the coding sequence. *Mol. Cell*. 35:139–40.
43. Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z. (2003) The microRNA world: small is mighty. *Trends Biochem. Sci.* 28:534–40.
44. Cheng H-YM, et al. (2007) microRNA modulation of circadian-clock period and entrainment. *Neuron*. 54:813–29.
45. Alvarez-Saavedra M, et al. (2011) miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. *Human Mol. Genet.* 20:731–51.
46. Hu L, et al. (2006) RACK1, a novel hPER1-interacting protein. *J. Mol. Neurosci.* 29:55–63.
47. Akashi M, Nishida E. (2000) Involvement of the MAP kinase cascade in resetting of the mammalian circadian clock. *Genes Dev.* 14:645–9.
48. Nakamura TJ, et al. (2010) Influence of the estrous cycle on clock gene expression in reproductive tissues: effects of fluctuating ovarian steroid hormone levels. *Steroids*. 75:203–12.
49. Winter SL, Bosnoyan-Collins L, Pinnaduwaage D, Andrusil IL. (2007) Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. *Neoplasia*. 9:797–800.
50. Kuo S-J, et al. (2009) Disturbance of circadian gene expression in breast cancer. *Virchows Arch.* 454:467–74.
51. Dai H, et al. (2011) The role of polymorphisms in circadian pathway genes in breast tumorigenesis. *Breast Cancer Res. Treatment*. 127:531–540.
52. Taniguchi H, et al. (2009) Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. *Cancer Res.* 69:8447–54.
53. Zhu Y, et al. (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. *Cancer Res.* 69:9315–22.
54. Zhu Y, et al. (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. *Int. J. Cancer*. 120:432–5.
55. Yang M-Y, et al. (2006) Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. *Cancer Sci.* 97:1298–307.
56. (2011) A snapshot of prostate cancer. Bethesda (MD): National Cancer Institute; [updated 2011 Oct; cited 2012 Oct 26]. Available from: <http://www.cancer.gov/cancertopics/types/prostate>
57. Cao Q, et al. (2009) A role for the clock gene Per1 in prostate cancer. *Cancer Res.* 69:7619–25.
58. Røe OD, et al. (2009) Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. *PLoS One*. 4:e6554.
59. Repouskou A, Sourlingas TG, Sekeri-Pataryas KE, Prombona A. (2010) The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells. *Chronobiol. Int.* 27:722–41.
60. Fujioka A, Takashima N, Shigeyoshi Y. (2006) Circadian rhythm generation in a glioma cell line. *Biochem. Biophys. Res. Commun.* 346:169–74.
61. Xia HC, et al. (2010) Deregulated expression of the Per1 and Per2 in human gliomas. *Can. J. Neurol. Sci.* 37:365–70.
62. Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC. (2006) Molecular overlap of fly circadian rhythms and human pancreatic cancer. *Cancer Lett.* 243:55–7.
63. Oda A, et al. (2009) Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. *Anticancer Res.* 29:1201–9.
64. Filipski E, et al. (2009) Circadian disruption accelerates liver carcinogenesis in mice. *Mutat. Res.* 680:95–105.
65. Davidson AJ, Straume M, Block GD, Menaker M. (2006) Daily timed meals dissociate circadian rhythms in hepatoma and healthy host liver. *Int. J. Cancer.* 118:1623–7.
66. Tokunaga H, et al. (2008) Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. *Acta Obstet. Gynecol. Scand.* 87:1060–70.
67. Shih M-C, Yeh K-T, Tang K-P, Chen J-C, Chang J-G. (2006) Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. *Mol. Carcinog.* 45:732–40.
68. Mazzoccoli G, et al. (2011) Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. *Chronobiol. Int.* 28:841–51.
69. Teboul M, Guillaumond F, Gréchez-Cassiau A, Delaunay F. (2008) Minireview: the nuclear hormone receptor family round the clock. *Mol. Endocrinol.* 22:2573–82.
70. Yang M-Y, et al. (2011) Altered expression of circadian clock genes in human chronic myeloid leukemia. *J. Biol. Rhythms.* 26:136–48.
71. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. (2010) Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. *PLoS One*. 5:e10995.
72. Yang X, et al. (2009) β -Catenin induces β -TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. *J. Biochem.* 145:289–97.
73. Pardo B, Gómez-González B, Aguilera A. (2009) DNA repair in mammalian cells. *Cell. Mol. Life Sci.* 66:1039–56.
74. Robertson A, Klungland A, Rognes T, Leiros I. (2009) DNA repair in mammalian cells. *Cell. Mol. Life Sci.* 66:981–93.
75. Liu L, Lee J, Zhou P. (2010) Navigating the nucleotide excision repair threshold. *J. Cell. Physiol.* 224:585–9.
76. Kang T-H, Reardon JT, Kemp M, Sancar A. (2009) Circadian oscillation of nucleotide excision repair in mammalian brain. *Proc. Natl. Acad. Sci. U. S. A.* 106:2864–7.
77. Kang TH, Sancar A. (2009) Circadian regulation of DNA excision repair: implications for chronotherapy. *Cell Cycle*. 8:1665–7.
78. Ikura T, et al. (2000) Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. *Cell*. 102:463–73.
79. Miyamoto N, et al. (2008) Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. *J. Biol. Chem.* 283:18218–26.
80. Yuan F, Gu L, Guo S, Wang C, Li G-M. (2004) Evidence for involvement of HMGB1 protein in human DNA mismatch repair. *J. Biol. Chem.* 279:20935–40.
81. Hoppe G, Rayborn ME, Sears JE. (2007) Diurnal rhythm of the chromatin protein Hmgb1 in rat photoreceptors is under circadian regulation. *J. Comp. Neurol.* 501:219–30.
82. Warner HR, Demple BF, Deutsch WA, Kane CM, Linn S. (1980) Apurinic/aprimidinic endonucleases in repair of pyrimidine dimers and other lesions in DNA. *Proc. Natl. Acad. Sci. U. S. A.* 77:4602–6.
83. Kimura H, Dong X, Yagita K, Okamura H. (2003) Brain expression of apurinic/aprimidinic endonuclease (APE/Ref-1) multifunctional DNA repair enzyme gene in the mouse with special reference to the suprachiasmatic nucleus. *Neurosci. Res.* 46:443–52.
84. Klevecz RR, Shymko RM, Blumenfeld D, Braly PS. (1987) Circadian gating of S phase in human ovarian cancer. *Cancer Res.* 47:6267–71.
85. You S, et al. (2005) Daily coordination of cancer growth and circadian clock gene expression. *Breast Cancer Res. Treat.* 91:47–60.
86. Brandi G, et al. (2004) Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. *Cancer Lett.* 208:193–6.
87. Sedivy R, Thurner S, Budinsky AC, Köstler WJ, Zielinski CC. (2002) Short-term rhythmic proliferation of human breast cancer cell lines: surface effects and fractal growth patterns. *J. Pathol.* 197:163–9.
88. Xiaoming Y, Wood PA, Ansell C, Hrushesky WJM. (2009) Circadian time-dependent tumor suppressor function of period genes. *Integr. Cancer Ther.* 8:309–16.
89. Gery S, et al. (2006) The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. *Mol. Cell.* 22:375–82.
90. Yang X, et al. (2009) The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. *Chronobiol. Int.* 26:1323–39.
91. Yang X, et al. (2009) Down regulation of circadian clock gene period 2 accelerates breast cancer growth by altering its daily growth rhythm. *Breast Cancer Res. Treat.* 117:423–31.
92. Lee CC. (2005) The Circadian Clock and Tumor Suppression by Mammalian Period Genes. In: *Methods in Enzymology*. Michael WY (ed.) Academic Press, pp. 852–861.

93. Miller BH, et al. (2007) Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. *Proc. Natl. Acad. Sci. U. S. A.* 104:3342–7.
94. Antoch MP, et al. (2008) Disruption of the circadian clock due to the clock mutation has discrete effects on aging and carcinogenesis. *Cell Cycle.* 7:1197–204.
95. Nakagawa H, et al. (2008) Modulation of circadian rhythm of DNA synthesis in tumor cells by inhibiting platelet-derived growth factor signaling. *J. Pharmacol. Sci.* 107:401–7.
96. van Zijl F, et al. (2009) Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. *Oncogene.* 28:4022–33.
97. Soares R, Guerreiro S, Botelho M. (2007) Elucidating progesterone effects in breast cancer: cross talk with PDGF signaling pathway in smooth muscle cell. *J. Cell. Biochem.* 100:174–83.
98. Ustach CV, Kim H-RC. (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. *Mol. Cell. Biol.* 25:6279–88.
99. Suzuki S, Heldin C-H, Heuchel R. (2007) Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. *BMC Cancer.* 7:224.
100. Kong D, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial–mesenchymal transition, adhesion, and invasion of prostate cancer cells. *Stem Cells.* 27:1712–21.
101. Ahmad A, et al. (2011) Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF- κ B signaling pathways. *Breast Cancer Res. Treat.* 126:15–25.
102. Fu W, Begley JC, Killen MW, Mattson MP. (1999) Anti-apoptotic role of telomerase in pheochromocytoma cells. *J. Biol. Chem.* 274:7264–71.
103. Qu Y, et al. (2003) Circadian telomerase activity and DNA synthesis for timing peptide administration. *Peptides.* 24:363–9.
104. Takane H, et al. (2001) Relationship between diurnal rhythm of cell cycle and interferon receptor expression in implanted-tumor cells. *Life Sci.* 68:1449–55.
105. Takane H, Ohdo S, Yamada T, Yukawa E, Higuchi S. (2000) Chronopharmacology of anti-tumor effect induced by interferon- β in tumor-bearing mice. *J. Pharmacol. Exp. Ther.* 294:746–52.
106. Faustino RS, et al. (2008) Ceramide regulation of nuclear protein import. *J. Lipid Res.* 49:654–62.
107. Wood PA, Xiaoming Yang, Hrshesky WJM. (2009) Clock genes and cancer. *Integr. Cancer Ther.* 8:303–8.
108. Foley P, et al. (2008) Targeted suppression of β -catenin blocks intestinal adenoma formation in APC Min mice. *J. Gastrointest. Surg.* 12:1452–8.
109. Krugluger W, et al. (2007) Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. *Cancer Res.* 67:7917–22.
110. Aisen P. (2004) Transferrin receptor 1. *Int. J. Biochem. Cell Biol.* 36:2137–43.
111. Boulton J, et al. (2008) Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. *Clin. Cancer Res.* 14:379–87.
112. Brookes MJ, et al. (2006) Modulation of iron transport proteins in human colorectal carcinogenesis. *Gut.* 55:1449–60.
113. Okazaki F, et al. (2010) Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. *Cancer Res.* 70:6238–46.
114. Mostafaie N, et al. (2009) Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. *Mol. Carcinog.* 48:642–7.
115. Eide EJ, et al. (2005) Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. *Mol. Cell. Biol.* 25:2795–807.
116. Meng Q-J, et al. (2008) Setting clock speed in mammals: the CK1tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins. *Neuron.* 58:78–88.
117. Yang WS, Stockwell BR. (2008) Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. *Genome Biol.* 9:R92.
118. Chen S-T, et al. (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. *Carcinogenesis.* 26:1241–6.
119. Suzuki T, et al. (2008) Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. *Biomed. Res.* 29:99–103.
120. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. (2010) Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. *J. Pineal Res.* 49:60–8.
121. Otálora BB, Madrid JA, Alvarez N, Vicente V, Rol MA. (2008) Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. *J. Pineal Res.* 44:307–15.
122. Gasser SM, Paro R, Stewart F, Aasland R. (1998) The genetics of epigenetics. *Cell. Mol. Life Sci.* 54:1–5.
123. Rottach A, Leonhardt H, Spada F. (2009) DNA methylation-mediated epigenetic control. *J. Cell. Biochem.* 108:43–51.
124. Lippman Z, May B, Yordan C, Singer T, Martienssen R. (2003) Distinct mechanisms determine transposon inheritance and methylation via small interfering RNA and histone modification. *PLoS Biol.* 1:e67.
125. Kulis M, Esteller M. (2010) 2 - DNA Methylation and Cancer. In: *Advances in Genetics.* Zdenko H, Toshikazu U (eds.) Academic Press, pp. 27–56.
126. Sansam CG, Roberts CWM. (2006) Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. *Cell Cycle.* 5:621–4.
127. Goodman JI, Counts JL. (1993) Hypomethylation of DNA: a possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis. *Environ. Health Perspect.* 101 Suppl 5:169–72.
128. Glaser KB, et al. (2004) Differential protein acetylation induced by novel histone deacetylase inhibitors. *Biochem. Biophys. Res. Commun.* 325:683–90.
129. Sawan C, Herceg Z. (2010) 3 - Histone Modifications and Cancer. In: *Advances in Genetics.* Zdenko H, Toshikazu U (eds.) Academic Press, pp. 57–85.
130. Cress WD, Seto E. (2000) Histone deacetylases, transcriptional control, and cancer. *J. Cell. Physiol.* 184:1–16.
131. Mottet D, Castronovo V. (2008) Histone deacetylases: target enzymes for cancer therapy. *Clin. Exp. Metastasis* 25:183–9.
132. Xu C-X, Krager SL, Liao D-F, Tischkau SA. (2010) Disruption of CLOCK-BMAL1 transcriptional activity is responsible for Aryl hydrocarbon receptor-mediated regulation of Period1 gene. *Toxicol. Sci.* 115:98–108.
133. Qu X, Metz RP, Porter WW, Cassone VM, Earnest DJ. (2007) Disruption of clock gene expression alters responses of the Aryl hydrocarbon receptor signaling pathway in the mouse mammary gland. *Mol. Pharmacol.* 72:1349–58.
134. Qu X, et al. (2010) The clock genes period 1 and period 2 mediate diurnal rhythms in dioxin-induced Cyp1A1 expression in the mouse mammary gland and liver. *Toxicol. Lett.* 196:28–32.
135. Qu X, Metz RP, Porter WW, Cassone VM, Earnest DJ. (2009) Disruption of period gene expression alters the inductive effects of dioxin on the AhR signaling pathway in the mouse liver. *Toxicol. Appl. Pharmacol.* 234:370–7.
136. Le Vee M, Jouan E, Fardel O. (2010) Involvement of aryl hydrocarbon receptor in basal and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes. *Toxicol. In Vitro.* 24:1775–81.
137. Garrett RW, Gasiewicz TA. (2006) The Aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin alters the circadian rhythms, quiescence, and expression of clock genes in murine hematopoietic stem and progenitor cells. *Mol. Pharmacol.* 69:2076–83.
138. Tischkau SA, Jaeger CD, Krager SL. (2011) Circadian clock disruption in the mouse ovary in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol. Lett.* 201:116–122.
139. Wheeler RH, et al. (1981) Glucocorticoid receptor activation and inactivation in cultured human lymphocytes. *J. Biol. Chem.* 256:434–41.
140. Robertson NM, Bodine PVN, Hsu T-C, Alnemri ES, Litwack G. (1995) Modulator inhibits nuclear translocation of the glucocorticoid receptor and inhibits glucocorticoid-induced apoptosis in the human leukemic cell line CEM C-7. *Cancer Res.* 55:548–56.
141. Ronacher K, et al. (2009) Ligand-selective transactivation and transrepression via the glucocor-

- ticoid receptor: role of cofactor interaction. *Mol. Cell. Endocrinol.* 299:219–31.
142. Dobos J, Kenessey I, Timar J, Ladanyi A. (2011) Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. *Pathol. Oncol. Res.* 17:729–34.
 143. Feng Y, Bai X, Yang Q, Wu H, Wang D. (2010) Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. *Int. J. Oncol.* 36:1541–9.
 144. Kay P, et al. (2011) Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. *PLoS One.* 6:e24839.
 145. Pan D, Kocherginsky M, Conzen SD. (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. *Cancer Res.* 71:6360–70.
 146. Gibbs JE, et al. (2009) Circadian timing in the lung: a specific role for bronchiolar epithelial cells. *Endocrinology.* 150:268–76.
 147. Charmandari E, et al. (2011) Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. *PLoS One.* 6:e25612.
 148. Kino T, Chrousos GP. (2011) Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. *Mol. Cell. Endocrinol.* 336:23–30.
 149. Nader N, Chrousos GP, Kino T. (2009) Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. *FASEB J.* 23:1572–83.
 150. Hoffman AE, et al. (2010) CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. *Cancer Res.* 70:1459–68.
 151. Chu LW, et al. (2008) Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. *Cancer Epidemiol. Biomarkers Prev.* 17:3268–73.
 152. Zhu Y, et al. (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. *Breast Cancer Res. Treat.* 107:421–5.
 153. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. (2007) The clock gene Per2 links the circadian system to the estrogen receptor. *Oncogene.* 26:7916–20.
 154. Saha S, Sassone-Corsi P. (2007) Circadian clock and breast cancer: a molecular link. *Cell Cycle.* 6:1329–31.
 155. Yasuniwa Y, et al. (2010) Circadian disruption accelerates tumor growth and angiostromagenesis through a Wnt signaling pathway. *PLoS One.* 5:e15330.
 156. Geusz ME, Blakely KT, Hiler DJ, Jamasbi RJ. (2010) Elevated mPer1 gene expression in tumor stroma imaged through bioluminescence. *Int. J. Cancer.* 126:620–30.
 157. Wang J, et al. (2008) Correlation of tumor growth suppression and methionine aminopeptidase-2 activity blockade using an orally active inhibitor. *Proc. Natl. Acad. Sci. U. S. A.* 105:1838–43.
 158. Yeh J-RJ, et al. (2006) Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. *Proc. Natl. Acad. Sci. U. S. A.* 103:10379–84.
 159. Nakagawa H, et al. (2004) 24-Hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins. *Cancer Res.* 64:8328–33.
 160. Maity G, Sen T, Chatterjee A. (2011) Laminin induces matrix metalloproteinase-9 expression and activation in human cervical cancer cell line (SiHa). *J. Cancer Res. Clin. Oncol.* 137:347–57.
 161. Venticinque L, Jamieson KV, Meruelo D. (2011) Interactions between laminin receptor and the cytoskeleton during translation and cell motility. *PLoS One.* 6:e15895.
 162. Scheiman J, Jamieson KV, Ziello J, Tseng JC, Meruelo D. (2010) Extraribosomal functions associated with the C terminus of the 37/67 kDa laminin receptor are required for maintaining cell viability. *Cell Death Dis.* 1:e42.
 163. Liu L, et al. (2010) Hypoxia promotes metastasis in human gastric cancer by up-regulating the 67-kDa laminin receptor. *Cancer Sci.* 101:1653–60.
 164. Ifuku M, et al. (2007) Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca²⁺ influx via reverse-mode activity of the Na⁺/Ca²⁺ exchanger. *J. Neurosci.* 27:13065–73.
 165. Nakahata Y, et al. (2008) The NAD⁺-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. *Cell.* 134:329–40.
 166. Kyrylenko S, Kyrylenko O, Suuronen T, Salmiinen A. (2003) Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. *Cell. Mol. Life Sci.* 60:1990–7.
 167. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. (2009) Role of sirtuin histone deacetylase SIRT1 in prostate cancer. *J. Biol. Chem.* 284:3823–32.
 168. Kim JE, Lou ZK, Chen JJ. (2009) Interactions between DBC1 and SIRT1 are deregulated in breast cancer cells. *Cell Cycle.* 8:3784–5.
 169. Noshko K, et al. (2009) SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Mod. Pathol.* 22:922–32.
 170. Olmos Y, Brosens JJ, Lam EWF. (2011) Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. *Drug Resistance Updates.* 14:35–44.
 171. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2007) Painting, fire-fighting, and shiftwork. Lyon (France); IARC. IARC monographs on the evaluation of carcinogenic risks to humans; vol. 98.
 172. Davis S, Mirick D. (2006) Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. *Cancer Causes Control.* 17:539–45.
 173. Dubocovich ML, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. *Pharmacol. Rev.* 62:343–80.
 174. Reiter RJ, Tan D-X, Fuentes-Broto L. (2010) Chapter 8 - Melatonin: A Multitasking Molecule. In: *Progress in Brain Research.* Luciano M (ed.) Elsevier, pp. 127–151.
 175. Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R. (2010) Altered time structure of neuro-endocrine-immune system function in lung cancer patients. *BMC Cancer.* 10:314.
 176. Hu S, Shen G, Yin S, Xu W, Hu B. (2009) Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer. *Adv. Ther.* 26:886–92.
 177. Galijasevic S, Abdulhamid I, Abu-Soud HM. (2008) Melatonin is a potent inhibitor for myeloperoxidase. *Biochemistry.* 47:2668–77.
 178. Roncucci L, et al. (2008) Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. *Cancer Epidemiol. Biomarkers Prev.* 17:2291–7.
 179. Wheatley-Price P, et al. (2008) Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. *Cancer.* 112:1037–42.
 180. Sliwinski T, et al. (2007) Protective action of melatonin against oxidative DNA damage: chemical inactivation versus base-excision repair. *Mutat. Res.* 634:220–7.
 181. Hill SM, et al. (2009) Molecular mechanisms of melatonin anticancer effects. *Integr. Cancer Ther.* 8:337–46.
 182. Blask DE, Dauchy RT, Brainard GC, Hanifin JP. (2009) Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. *Integr. Cancer Ther.* 8:347–53.
 183. Flynn-Evans E, Stevens R, Tabandeh H, Scherhammer E, Lockley S. (2009) Total visual blindness is protective against breast cancer. *Cancer Causes Control.* 20:1753–6.
 184. Hevia D, et al. (2008) Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion. *J. Pineal Res.* 45:247–57.
 185. Kayumov L, Lowe A, Rahman SA, Casper RF, Shapiro CM. (2007) Prevention of melatonin suppression by nocturnal lighting: relevance to cancer. *Eur. J. Cancer Prev.* 16:357–62.
 186. Stevens RG. (2009) Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. *Int. J. Epidemiol.* 38:963–70.
 187. Stevens R, Rea M. (2001) Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. *Cancer Causes Control.* 12:279–87.
 188. Stevens RG, et al. (2007) Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. *Environ. Health Perspect.* 115:1357–62.

189. Giacchetti S, *et al.* (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. *J. Clin. Oncol.* 24:3562–9.
190. Bouchahda M, *et al.* (2009) Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. *Cancer.* 115:4990–9.
191. Lévi F, *et al.* (2011) Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. *Cancer Chemother. Pharmacol.* 67:339–48.
192. Asao T, *et al.* (2006) The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer. *Int. J. Hyperthermia.* 22:399–406.
193. Weinrib AZ, *et al.* (2010) Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. *Cancer.* 116:4410–9.
194. Bower JE, *et al.* (2005) Diurnal cortisol rhythm and fatigue in breast cancer survivors. *Psychoneuroendocrinology.* 30:92–100.
195. Bower JE, Ganz PA, Aziz N. (2005) Altered cortisol response to psychologic stress in breast cancer survivors with persistent Fatigue. *Psychosom. Med.* 67:277–80.
196. Abercrombie HC, *et al.* (2004) Flattened cortisol rhythms in metastatic breast cancer patients. *Psychoneuroendocrinology.* 29:1082–92.
197. Johansson A-C, *et al.* (2008) Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. *Eur. J. Pain.* 12:633–40.
198. Rich T, *et al.* (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. *Clin. Cancer Res.* 11:1757–64.
199. Sephton SE, *et al.* (2009) Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. *Brain Behav. Immun.* 23:1148–55.
200. Fang MZ, Zhang X, Zarbl H. (2010) Methylselenocysteine resets the rhythmic expression of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo. *Cancer Prev. Res.* 3:640–52.
201. Zhang X, Zarbl H. (2008) Chemopreventive doses of methylselenocysteine alter circadian rhythm in rat mammary tissue. *Cancer Prev. Res.* 1:119–27.
202. Hua H, *et al.* (2007) Inhibition of tumorigenesis by intratumoral delivery of the circadian gene *mPer2* in C57BL/6 mice. *Cancer Gene Ther.* 14:815–8.
203. Iurisci I, *et al.* (2006) Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. *Cancer Res.* 66:10720–8.
204. Bernard S, Cajavec Bernard B, Lévi F, Herzel H. (2010) Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. *PLoS Comput. Biol.* 6:e1000712.
205. Shukla P, *et al.* (2010) Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. *Cancer.* 116:2031–5.
206. Rahn DA, *et al.* (2011) Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? *Cancer.* 117:414–20.
207. Innominato PF, Lévi FA, Bjarnason GA. (2010) Chronotherapy and the molecular clock: clinical implications in oncology. *Adv. Drug Delivery Rev.* 62:979–1001.
208. Mormont M-C, Lévi F. (2003) Cancer chronotherapy: principles, applications, and perspectives. *Cancer.* 97:155–69.
209. Hrushesky WJM, *et al.* (2009) Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. *Integr. Cancer Ther.* 8:387–97.
210. Ohdo S, Koyanagi S, Matsunaga N. (2010) Chronopharmacological strategies: intra- and inter-individual variability of molecular clock. *Adv. Drug Deliv. Rev.* 62:885–97.